What's a fair offer from Pfizer?, page-35

Not from their last quarterly and even the recent pilot of using ResAppDx-EU for another sector by the NHS, we will know more in 2 weeks time and what management real intention is and I'm leaning toward the later. I can honestly see the pps double to 20c after the T/O bid is rejected mid June particular if this quarter show double the customer revenue to $300K and this recent PR. It won't surprise me if RAP also signed up a few more license agreement for ResAppDx-EU in this 2 months due to this PR.......